지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 375 - 386 (12page)
이용수
초록· 키워드
오류제보하기
Background/Aims: Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of the α4β7 inhibitor abrilumab in Japanese patients with moderate-to-severe UC despite conventional treatments. Methods: In this randomized, double-blind, placebo-controlled study, 45 UC patients were randomized to abrilumab 21 mg (n=11), 70 mg (n=12), 210 mg (n=9), or placebo (n=13) via subcutaneous (SC) injection for 12 weeks. The double-blind period was followed by a 36-week open-label period, in which all patients received abrilumab 210 mg SC every 12 weeks, and a 28-week safety follow-up period. The primary efficacy variable was clinical remission at week 8 (total Mayo score ≤2 points with no individual subscore >1 point). Results: Clinical remission at week 8 was 4 out of 31 (12.9%) overall in the abrilumab groups versus 0 out of 13 in the placebo group (abrilumab 21 mg, 1/10 [10.0%]; 70 mg, 2/12 [16.7%]; 210 mg, 1/9 [11.1%]). In both the double-blind and open-label periods, fewer patients in the abrilumab groups experienced ≥1 adverse event compared with those in the placebo group. There were no cases of progressive multifocal leukoencephalopathy and no deaths. Conclusions: Abrilumab 70 mg and 210 mg yielded numerically better results in terms of clinical remission rate at Week 8 than placebo, with the 210 mg dose showing more consistent treatment effects. Abrilumab was well tolerated in Japanese patients with UC.
목차
등록된 정보가 없습니다.
참고문헌 (24)
참고문헌 신청
Ministry of Health, Labour and Welfare / Shared Study Report FY 2016 on “Research on intractable inflammatory bowel disease”(Suzuki Group). Ulcerative colitis/Crohn’s disease diagnostic criteria/treatment guideline
Cosnes J / 2011 / Epidemiology and natural history of inflammatory bowel diseases / Gastroenterology 140:1785~1794
Prideaux L / 2012 / Inflammatory bowel disease in Asia : a systematic review / J Gastroenterol Hepatol 27:1266~1280
2010 Public Health Report (Table 65 No. of patients receiving medical treatment for refractory diseases by sex, age group and disease) / Ministry of Health, Labour and Welfare Web site
Asakura K / 2009 / Prevalence of ulcerative colitis and Crohn’s disease in Japan / J Gastroenterol 44:659~665
Cosnes J / 2011 / Epidemiology and natural history of inflammatory bowel diseases / Gastroenterology 140:1785~1794
Prideaux L / 2012 / Inflammatory bowel disease in Asia : a systematic review / J Gastroenterol Hepatol 27:1266~1280
2010 Public Health Report (Table 65 No. of patients receiving medical treatment for refractory diseases by sex, age group and disease) / Ministry of Health, Labour and Welfare Web site
Asakura K / 2009 / Prevalence of ulcerative colitis and Crohn’s disease in Japan / J Gastroenterol 44:659~665
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials
Gut and Liver
2016 .01
-
Ulcerative Colitis and Patient’s Quality of Life, Especially in Early Stage
Gut and Liver
2022 .05
-
Factors related to Quality of Life of Patients with Ulcerative Colitis
성인간호학회 학술대회
2015 .04
-
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Intestinal research
2021 .10
-
Is the Long-term Disease Course of Elderly-Onset Ulcerative Colitis Different from That of Non-Elderly-Onset Ulcerative Colitis?
Gut and Liver
2021 .09
-
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
Intestinal research
2023 .01
-
Current and Emerging Biologics for Ulcerative Colitis
Gut and Liver
2015 .01
-
청소년궤양성 대장염 환자의 사상체질요법에 대한 증례보고
대한한방내과학회지
2017 .01
-
One-year clinical efficacy and safety of indigo naturalis for active ulcerative colitis: a real-world prospective study
Intestinal research
2022 .04
-
한약치료를 통해 관해가 유도된 궤양성대장염 환자: 증례보고
Korean Journal of Acupuncture
2019 .01
-
Endoscopic Mucosal Healing as a Treatment Target in Ulcerative Colitis: Does It Have the Same Role in Asian Patients?
Gut and Liver
2021 .11
-
Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
Intestinal research
2022 .04
-
The role and prospect of tofacitinib in patients with ulcerative colitis
Intestinal research
2023 .01
-
Ustekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing
Intestinal research
2024 .07
-
Clinical Characteristics and Long-term Outcomes of Pediatric Ulcerative Colitis: A Single-Center Experience in Korea
Gut and Liver
2022 .03
-
Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naive Patients with Ulcerative Colitis
Gut and Liver
2021 .01
-
Irritable bowel syndrome-like symptoms associated with endoscopic activity predict ulcerative colitis relapse in patients with clinical remission
Intestinal research
2017 .01
-
Laparoscopic surgery contributes to a decrease in short-term complications in surgical ulcerative colitis patients during 2008–2017: a multicenter retrospective study in China
Intestinal research
2023 .04
-
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Intestinal research
2023 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0